Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Shanghai - Delayed Quote CNY

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS)

Compare
65.00
-0.18
(-0.28%)
At close: 3:00:02 PM GMT+8
Loading Chart for 603392.SS
  • Previous Close 65.18
  • Open 64.87
  • Bid 65.00 x --
  • Ask 65.02 x --
  • Day's Range 64.65 - 65.50
  • 52 Week Range 61.90 - 89.89
  • Volume 1,390,424
  • Avg. Volume 2,804,824
  • Market Cap (intraday) 82.461B
  • Beta (5Y Monthly) 2.25
  • PE Ratio (TTM) --
  • EPS (TTM) -0.23
  • Earnings Date Apr 12, 2025
  • Forward Dividend & Yield 0.32 (0.49%)
  • Ex-Dividend Date Jun 3, 2024
  • 1y Target Est --

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides chemiluminescence series, assembly line series, nucleic acid series, dry type fluorescent immunoassay, and fully automatic blood type analyzer and reagents; ELISA kits; rapid diagnosis; bole series; and supporting reagents. The company was founded in 1991 and is headquartered in Beijing, China.

www.ystwt.com

3,843

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 603392.SS

View More

Performance Overview: 603392.SS

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

603392.SS
7.75%
SSE Composite Index (000001.SS)
0.29%

1-Year Return

603392.SS
1.60%
SSE Composite Index (000001.SS)
8.89%

3-Year Return

603392.SS
51.37%
SSE Composite Index (000001.SS)
1.81%

5-Year Return

603392.SS
1,366.11%
SSE Composite Index (000001.SS)
20.91%

Compare To: 603392.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 603392.SS

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    82.46B

  • Enterprise Value

    77.89B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    33.09

  • Price/Book (mrq)

    6.64

  • Enterprise Value/Revenue

    31.28

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -11.81%

  • Return on Assets (ttm)

    -1.54%

  • Return on Equity (ttm)

    -2.26%

  • Revenue (ttm)

    2.49B

  • Net Income Avi to Common (ttm)

    -294.04M

  • Diluted EPS (ttm)

    -0.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.5B

  • Total Debt/Equity (mrq)

    2.21%

  • Levered Free Cash Flow (ttm)

    28.87M

Research Analysis: 603392.SS

View More

Company Insights: 603392.SS

Research Reports: 603392.SS

View More

People Also Watch